KingMed Diagnostics Group led the round! Metabolomics Leader Biotree Completes CNY 10 Million Series A+ Financing

On January 3, 2023, Shanghai Biotree BIOTECH Co., Ltd. (hereinafter referred to as "Biotree"), a leading Chinese metabolomics research company, announced the completion of a strategic financing round of CNY 10 Million A+. This round of financing was led by KingMed Diagnostics Group and its shareholding fund Kejin Jinyu, and followed by its old shareholder Qiming Venture Partners.

Currently, precision medicine has put forward higher requirements for precision diagnosis technology, and the importance of metabolomics, proteomics and other multi-omics technologies in life science field is increasingly prominent. Biotree has been deeply engaged in metabolomics technology for more than ten years, and has established a perfect detection and analysis platform for non-targeted metabolomics, high-throughput targeted metabolomics, lipidomics, metabolic flow, proteomics, single-cell omics and antibody sequencing. The company aims to pioneer the Chinese metabolomics research service market by conducting multi-omics research such as metabolomics and proteomics and transforming the research results into early screening or diagnostic innovation products that can be applied to clinical and general health through its core technologies.

The financing funds will be used to promote the research and development of the company's innovative products such as colorectal cancer early screening kits and small mass spectrometry dedicated machines, and further strengthen the investment in the research and development of new products in metabolomics and proteomics to promote the rapid development of mass spectrometry detection technology in scientific research, pharmaceutical companies and clinical application scenarios, with a view to filling the gaps of domestic metabolomics and proteomics in the field of early screening. KingMed Diagnostics Group is not only the lead investor, but will also carry out comprehensive cooperation with Biotree in multiple fields such as metabolomics and other multi-omics scientific research services, translational development of innovative clinical mass spectrometry projects.

Yiwen Jin, Vice President of KingMed Diagnostics Group, said, "Metabolomics, proteomics and other multi-omics technologies have very broad prospects for application in the medical testing field. Biotree has core competencies in metabolomics database and data analysis platform. We are glad to enter into a strategic partnership with Biotree and participate in the development of Biotree. This is also one of the important directions for KingMed Diagnostics Group to build the 'Medical Testing+' ecosystem. KingMed Diagnostics will take advantage of its 'big platform, big network, big services, big samples and big data' and other resources to join hands with Biotree and work together in good faith to provide leading metabolomics research and medical testing services for clinical purposes."

Junliang Deng, Founder and CEO of Biotree, said, "Biotree is dedicated to the research and application of multi-omics technologies such as metabolomics and proteomics on biological samples, and to transform the research results into innovative products that can be applied to clinical early screening and diagnosis to help early detection and early diagnosis, thus enhancing the quality of life. This is the original intention of Biotree. We are very grateful for the recognition and support from our investors in this round, KingMed Diagnostics Group, Kejin Jinyu and our old shareholder Qiming Venture Partners, and believe that with the strategic support from KingMed Diagnostics Group, we can accelerate the innovative products of Biotree to the market and benefit the people as soon as possible."

Lijun Kuang, Chairman of Guangzhou Financial Innovation Investment Holding Co., Ltd., said: "Kejin Jinyu Fund is a private equity fund jointly launched by Guangzhou Financial Innovation Investment Holding CO., Ltd. and KingMed Diagnostics, focusing on investing in high-tech innovative projects in the field of IVD and medical testing and other fields of big health industry. This investment in Biotree is a focus on its application prospect and R&D strength based on innovative mass spectrometry technology and multi-omics diagnostic technology in the field of life and health, and we hope to help it develop for the better, so that more high-quality diagnostic technologies can be applied to the clinic as early as possible to guard people's health."